RayThera focuses on creating innovative small molecule therapies, particularly in the field of immunology, addressing critical unmet medical needs. The company utilizes decades of drug discovery expertise to enhance the development process while upholding stringent standards.
Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain. The company aims to target pain at its source to provide effective, rapid-acting pain relief without the risk of addiction. Their lead program targets Nav1.8, a validated human pain target, leveraging internal ion channel expertise.
Eikon Therapeutics, Inc. is a biopharmaceutical company based in Hayward, California, focused on developing innovative treatments for chronic and life-threatening diseases. Founded in 2019, the company employs advanced super-resolution microscopy and live-cell imaging techniques to discover drugs targeting previously intractable proteins. By integrating biology, engineering, and chemistry, Eikon Therapeutics aims to enhance the understanding of cellular processes and improve drug discovery efficiency. Its proprietary platforms allow for the sensitive identification of compound-protein interactions, enabling the direct measurement of how chemical compounds affect individual proteins in live cells. This novel approach seeks to unlock new therapeutic opportunities and expand the company's pipeline of potential medications.
Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Based in Newton, Massachusetts, Abcuro creates therapeutic antibodies targeting novel mechanisms related to these diseases. The company utilizes advanced bioinformatics to analyze transcription data from human diseases, which aids in the identification of new therapeutic targets. Through ex-vivo validation in diseased tissues, Abcuro seeks to uncover innovative methods to modulate key components of the immune system. Established in 2015, Abcuro aims to enhance treatment strategies in the healthcare industry by offering effective solutions for complex immunological conditions.
RAPT Therapeutics is a clinical-stage biopharmaceutical company specializing in immunology. It focuses on discovering, developing, and commercializing oral small-molecule therapies aimed at addressing significant unmet medical needs in oncology and inflammatory diseases. RAPT's proprietary discovery engine has led to the advancement of two drug candidates: FLX475, which selectively inhibits the migration of immunosuppressive regulatory T cells into tumors, and RPT193, which targets type 2 T helper cells in inflamed tissues. Both candidates have progressed to clinical trials within a short time frame since the company's inception. Additionally, RAPT is exploring further therapeutic targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, which are currently in the discovery phase.
Ikena Oncology is a biotechnology company based in Boston, Massachusetts, focused on developing innovative therapies for cancer treatment. The company specializes in biomarker-driven and precision therapies that target specific mechanisms involved in cancer growth, spread, and resistance. Its product pipeline includes several candidates such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-930, an oral small-molecule inhibitor of the TEAD transcription factor in the Hippo signaling pathway. Additionally, Ikena is exploring a kynurenine-degrading enzyme with IK-412 and other discovery-stage programs targeting various oncogenic pathways. Established in 2016, Ikena Oncology aims to address unmet medical needs through a combination of chemistry, translational science, and patient-centered drug development.
Pleno is a biotechnology company based in San Diego, California, founded in 2017. The company focuses on accelerating disease diagnosis and treatment through its innovative Hypercoding technology, which utilizes signal processing techniques from the telecommunications industry. Pleno has developed a multi-omic instrument for biological target detection that significantly enhances clinical testing and biomedical research. This platform is capable of monitoring minimal residual disease and facilitating early multi-cancer screenings. It also detects a wide array of analytical targets, including DNA, RNA, and protein biomarkers, with exceptional speed and precision. Additionally, Pleno employs advanced microfluidics to automate sample preparation and analysis, thereby providing healthcare providers with diverse health monitoring technologies.
Sollis Health, previously known as Priority Private Care, provides comprehensive medical services focused on urgent and emergency care. The company offers members access to top-tier medical facilities and ER physicians who oversee their care from check-in to follow-up. With a commitment to personalized service, Sollis Health ensures that members receive attentive support and advanced diagnostic imaging. Their offerings include round-the-clock medical care, preventative health assessments, healthcare advocacy, and a network of selected specialists, all designed to enhance the patient experience during acute medical emergencies. The organization aims to deliver a seamless and superior healthcare experience, functioning like a personal doctor available at all times.
Chimagen Biosciences is focused on developing a novel class of multi-functional monoclonal antibodies specifically for cancer therapy. The company engages in the discovery and development of these therapeutic antibodies and conducts clinical studies to evaluate their effectiveness. By aiming to address unmet medical needs in oncology, Chimagen Biosciences seeks to deliver innovative treatment options for patients battling cancer.
Seaport Therapeutics is a clinical stage biopharmaceutical company focused on developing innovative neuropsychiatric medicines for patients with significant unmet needs. The company's approach emphasizes the creation of treatments that offer oral bioavailability, which allows the medications to bypass first-pass metabolism. This method aims to reduce hepatotoxicity and other adverse side effects commonly associated with neuropsychiatric treatments. By addressing these critical issues, Seaport Therapeutics seeks to improve the quality of life for individuals living with neuropsychiatric disorders.
Foresight Diagnostics specializes in developing innovative liquid biopsy tests aimed at measuring minimal residual disease, which assists in patient management for cancer care. The company’s technology enables early cancer detection through a simple blood sample, utilizing the unique biological characteristics that differentiate cancer cells from healthy cells. This approach allows healthcare professionals to identify smaller tumors earlier and implement personalized treatment strategies tailored to individual patients. Foresight Diagnostics has attracted considerable interest from multiple pharmaceutical companies in the oncology sector, indicating a strong potential for collaboration and advancement in cancer diagnosis and treatment.
Spear Bio is a biotechnology company established in 2021 and located in Weston, Massachusetts. The company specializes in ultrasensitive protein detection technology, which provides significant advantages in the healthcare sector. Its innovations support self-testing and telemedicine-based diagnostics by enabling the quantification of minute protein biomarkers from samples collected at home. This approach allows clinicians to achieve ultrasensitive detection using small sample volumes, seamlessly integrating into existing workflows for sample collection, processing, and analysis.
Thyme Care is a healthcare company focused on providing comprehensive oncology care management services. It partners with health plans to deliver an integrated oncology solution that emphasizes whole-person care for cancer patients. By employing a tech-enabled platform, Thyme Care offers personalized support through physician-guided oncology nurses and resource specialists who educate and guide patients throughout their cancer journey. This model generates actionable insights that help healthcare providers identify at-risk patients earlier, facilitating timely access to quality resources and care. Thyme Care aims to enhance the cancer experience through early and ongoing intervention, ensuring that every cancer patient receives the individualized care they need.
Element Biosciences, Inc. is a life science company based in San Diego, California, that specializes in developing innovative genetic analysis tools for research and diagnostics. Established in 2017, the company focuses on creating a modular and high-performing DNA sequencing platform designed to provide high-quality data and workflow flexibility. Their proprietary technology enhances the signal-to-noise ratio and incorporates advancements in surface chemistry, instrumentation, and biochemistry. This approach significantly reduces both operational and capital costs while ensuring superior sequencing data quality, thereby making next-generation sequencing technology more accessible to medical researchers and improving their research capabilities.
CASI Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics, particularly in the fields of hematology and oncology. The company focuses on addressing unmet medical needs by acquiring and advancing various pharmaceutical products. Among its offerings, EVOMELA is notable for its role as a conditioning treatment prior to autologous stem cell transplants in multiple myeloma patients, while its portfolio also includes CID-103, CNCT19, MARQIBO, ZEVALIN, and ENMD-2076. CASI Pharmaceuticals primarily generates revenue through the sales of EVOMELA, and it aims to establish itself as a leader in the biopharmaceutical sector by leveraging its expertise in drug development and regulatory processes, particularly in the China market.
enGene is a developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal immunotherapy platform has developed a flexible nucleotide delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels, enabling physicians and doctors to regenerate physiologic, meal-regulated insulin secretion from the gut of subjects with diabetes.
Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain. The company aims to target pain at its source to provide effective, rapid-acting pain relief without the risk of addiction. Their lead program targets Nav1.8, a validated human pain target, leveraging internal ion channel expertise.
Genomics plc is focused on transforming healthcare through advanced genomic analysis. The company employs sophisticated methodologies to analyze large integrated datasets of genomic and phenotypic information, aiming to enhance understanding of human biology. By leveraging genetic inference technology, Genomics plc seeks to identify new drug targets for serious diseases and assess individual disease risk. Their analytical platform enables the exploration of genomic sequence data, providing valuable insights that support pharmaceutical companies in reducing risks associated with drug development. This approach not only aims to improve healthcare outcomes but also sets a standard for how organizations and patients can benefit from genomic data.
Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies that target RNA processing to address various diseases. Established in 2018 and based in Cambridge, Massachusetts, the company employs its proprietary biology platform to identify and prioritize therapeutic targets within RNA processing. Through its REMseq platform, Remix Therapeutics validates potential drug targets and optimizes chemical compounds for therapeutic use. The company's approach aims to reprogram RNA processing to control gene expression, thereby correcting, enhancing, or eliminating problematic gene messages. This enables healthcare providers to tackle the underlying causes of diseases, offering novel solutions to previously undruggable conditions.
Thyme Care is a healthcare company focused on providing comprehensive oncology care management services. It partners with health plans to deliver an integrated oncology solution that emphasizes whole-person care for cancer patients. By employing a tech-enabled platform, Thyme Care offers personalized support through physician-guided oncology nurses and resource specialists who educate and guide patients throughout their cancer journey. This model generates actionable insights that help healthcare providers identify at-risk patients earlier, facilitating timely access to quality resources and care. Thyme Care aims to enhance the cancer experience through early and ongoing intervention, ensuring that every cancer patient receives the individualized care they need.
CG Oncology is a clinical-stage biopharmaceutical company dedicated to developing innovative immunotherapies for cancer treatment, particularly focusing on bladder cancer. The company specializes in oncolytic immunotherapies, with its lead candidate, cretostimogene grenadenorepvec, designed as a targeted, intravesical immunotherapy. Currently, CG Oncology is conducting multiple clinical trials, including two phase three trials aimed at high-risk patients with non-muscle invasive bladder cancer (NMIBC) who are unresponsive to BCG therapy, as well as an additional phase two study in combination with a checkpoint inhibitor. The company aims to provide effective bladder-sparing treatment options for patients while advancing the development of its proprietary therapies.
Pharvaris is a clinical-stage company dedicated to the discovery and development of therapies for rare diseases, particularly focusing on hereditary angioedema (HAE) and other conditions mediated by bradykinin. The company is advancing an oral bradykinin B2 receptor antagonist, with its lead candidate, PHA121, currently undergoing Phase 1 clinical trials. Pharvaris aims to provide new treatment options that offer alternatives to injected therapies for all sub-types of HAE. The company was co-founded by key individuals involved in the development of icatibant, a previously established treatment for HAE, ensuring a strong foundation in this therapeutic area.
Foresight Diagnostics specializes in developing innovative liquid biopsy tests aimed at measuring minimal residual disease, which assists in patient management for cancer care. The company’s technology enables early cancer detection through a simple blood sample, utilizing the unique biological characteristics that differentiate cancer cells from healthy cells. This approach allows healthcare professionals to identify smaller tumors earlier and implement personalized treatment strategies tailored to individual patients. Foresight Diagnostics has attracted considerable interest from multiple pharmaceutical companies in the oncology sector, indicating a strong potential for collaboration and advancement in cancer diagnosis and treatment.
Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom, the company utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, using a repository of over 15,000 human brain tissue samples. This platform provides detailed expression and epigenetic data, allowing Cerevance to identify promising therapeutic targets for central nervous system diseases. Through its research, the company aims to advance new medicines that can potentially address the underlying mechanisms of these debilitating conditions.
evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniques we are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines.
Galileo, Inc. is a technology company that specializes in providing healthcare solutions through a mobile application, enabling direct access to clinical care and expertise via smartphones. Founded in 2014 and headquartered in New York, the company facilitates communication between healthcare providers and patients using advanced telecommunications technologies. Galileo delivers high-touch, data-driven, multi-specialty care to a diverse patient population, offering services over the phone and in various settings. The company is recognized by regional and national health plans, employers, and major corporations for its effectiveness in enhancing population health. Galileo's mission is to address complex healthcare challenges and foster closer connections between patients and providers.
Detect they build tools that empower people to understand their health.
Pleno is a biotechnology company based in San Diego, California, founded in 2017. The company focuses on accelerating disease diagnosis and treatment through its innovative Hypercoding technology, which utilizes signal processing techniques from the telecommunications industry. Pleno has developed a multi-omic instrument for biological target detection that significantly enhances clinical testing and biomedical research. This platform is capable of monitoring minimal residual disease and facilitating early multi-cancer screenings. It also detects a wide array of analytical targets, including DNA, RNA, and protein biomarkers, with exceptional speed and precision. Additionally, Pleno employs advanced microfluidics to automate sample preparation and analysis, thereby providing healthcare providers with diverse health monitoring technologies.
FOLX Health is a telehealth platform based in Boston, Massachusetts, that specializes in providing digital healthcare services for the LGBTQIA+ community. Launched in 2020, the platform creates a medical service marketplace specifically designed for queer and trans individuals. FOLX Health offers access to a network of clinicians who understand the unique needs of this community, focusing on services such as gender-affirming hormone therapy, sexual health, and family creation. The platform also provides virtual consultations, discreet delivery of at-home medication kits, and general medical services, aiming to eliminate the barriers and stigma often encountered in traditional healthcare settings. By prioritizing the health and well-being of LGBTQIA+ individuals, FOLX Health fosters a supportive environment for patients to manage their health needs.
Nested Therapeutics is a Cambridge-based VC-backed stealth biotech company. The company's focus is on finding and creating new precision oncology small-molecule drugs targeted toward cancer genes. Nested Therapeutics was established in 2021 in Cambridge, Massachusetts.
Myome is a company focused on gene analytics technology that aims to enhance understanding of how DNA influences health and well-being. By utilizing genome sequencing, Myome provides insights into a range of common and rare diseases, including coronary heart disease. This technology allows for the estimation of risks associated with various multifactorial medical conditions, empowering families to take proactive measures to reduce the transmission of genetic diseases across generations. The data generated by Myome is designed to be secure, portable, and reusable throughout an individual's life, facilitating ongoing health management.
Mirvie is a biotech company focused on developing non-invasive tests aimed at improving maternal-fetal health. Founded in 2018 and based in South San Francisco, California, Mirvie offers a medical diagnostic platform that provides actionable insights for mothers and families throughout their pregnancy journey. The company's innovative predictive tests help medical practitioners identify at-risk pregnancies, allowing for timely interventions and enhanced management of pregnancy-related concerns. By prioritizing safety and health, Mirvie seeks to empower families with the information necessary for better pregnancy outcomes.
Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies that target RNA processing to address various diseases. Established in 2018 and based in Cambridge, Massachusetts, the company employs its proprietary biology platform to identify and prioritize therapeutic targets within RNA processing. Through its REMseq platform, Remix Therapeutics validates potential drug targets and optimizes chemical compounds for therapeutic use. The company's approach aims to reprogram RNA processing to control gene expression, thereby correcting, enhancing, or eliminating problematic gene messages. This enables healthcare providers to tackle the underlying causes of diseases, offering novel solutions to previously undruggable conditions.
Kriya Therapeutics, Inc. is a gene therapy company dedicated to designing and developing treatments for chronic diseases. Founded in 2019 and headquartered in Palo Alto, California, with an additional office in Durham, North Carolina, the company has established a fully integrated platform that consolidates the essential infrastructure and technology for creating, manufacturing, and developing gene therapies. Kriya Therapeutics employs a vector design platform that enhances its ability to undertake novel construct design, targeted sequence modification, and comprehensive data analysis. This approach aims to reduce immunogenicity and improve tissue specificity, ultimately enabling physicians to provide more effective therapeutic options for patients.
DNAnexus, Inc. is a provider of cloud-based genome informatics and data management tools aimed at enterprises engaged in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and integration with clinical and phenotypic data, promoting seamless collaboration among users. Key offerings include MOSAIC Microbiome, a platform for collaborative microbiome research; DNAnexus Apollo, which focuses on clinico-genomic data exploration; and DNAnexus Titan, a comprehensive data analysis solution. Additionally, DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration. The Clinico-Genomic Data Solution program addresses the need for disease-specific datasets by building networks with healthcare partners to enhance diagnosis and treatment pathways. DNAnexus serves a diverse client base, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.
TenSixteen Bio is a biotechnology company focused on developing novel therapeutics for a variety of diseases. The company uses somatic mosaicism and clonal hematopoiesis (CHIP) to find and develop new treatments for age-related disorders. Foresite Labs co-founded TenSixteen Bio, which is based in San Francisco.
ImmPACT Bio USA Inc. is a cell therapy company focused on developing engineered T-cells specifically designed to target and treat solid tumors. By utilizing advanced technology, the company aims to create chimeric antigen receptor (CAR) T-cell therapies that exhibit tumor specificity, allowing them to induce cytotoxicity only when interacting with tumor cells while sparing healthy tissues. This selective targeting mitigates the safety risks commonly associated with existing CAR-T therapies, providing a promising approach to cancer treatment that enhances efficacy and reduces potential harm to noncancerous cells.
Maze Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative medicines that leverage the effects of rare genetic variants to address unmet medical needs. Founded in 2017 and originally known as Modulus Therapeutics, the company utilizes its proprietary Compass platform to identify genetic variants linked to diseases and map them to the biological pathways that drive these conditions in specific patient populations. By integrating large-scale human genetics data and functional genomics with various drug discovery methods, Maze Therapeutics aims to reveal modifier genes that offer protective benefits. This approach enhances the understanding of target biology and informs the development of novel therapies, ultimately enabling pharmaceutical companies to create effective treatments.
Developer of transformative biotech company intended to create, annotate and biologically understand the world's most rigorous and extensive library of microproteins and produce entirely new, novel therapeutics. The company's technology identify novel, protein coding sequences hidden within the human genome, these small proteins mediate rich and diverse human biology, thereby harnessing the therapeutic potential of a novel class of human peptides.
Pardes Biosciences is a clinical-stage biopharmaceutical company focused on addressing significant health challenges, particularly those posed by viral infections. It utilizes modern reversible-covalent chemistry to discover and develop novel oral drug candidates. The company's lead product candidate, PBI-0451, is an oral antiviral designed to treat and prevent infections from SARS-CoV-2, the virus responsible for COVID-19. By reimagining the patient journey, Pardes aims to provide accessible and convenient treatment options for both adult and pediatric patients, ultimately striving to improve health outcomes and respond effectively to global health crises.
Tasso, Inc. is a Seattle-based company founded in 2012 that specializes in manufacturing blood sample collection devices designed for patient convenience. The company's innovative devices enable individuals to collect their own blood samples safely and easily at home, eliminating the need for clinic visits. These disposable, compact devices feature interchangeable cartridges that ensure proper blood preparation immediately upon sample collection. By allowing patients to manage their blood sampling process, Tasso aims to streamline blood-based diagnostics and enhance the overall experience of medical testing.
Mythic Therapeutics is a biotechnology company dedicated to advancing cancer treatment through innovative antibody-drug conjugates (ADCs). The company specializes in a protein engineering approach that enhances the potency of ADCs while maintaining safety, allowing for more effective targeted therapies across various tumor types. By improving the uptake of these therapeutics in cancerous cells and minimizing payload release in healthy cells, Mythic Therapeutics aims to increase the efficacy of treatments without causing significant side effects or toxicity. This technology positions the company to make a meaningful impact in cancer care, enabling healthcare practitioners to better utilize ADCs for a wide array of patients.
Odyssey Therapeutics is a biotechnology company focused on developing next-generation immunomodulators and oncology drugs. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, identifying promising targets while reducing the likelihood of failure during development. Odyssey Therapeutics is committed to advancing the field of drug discovery and expediting clinical development, ultimately contributing to the creation of more effective precision medicines for the healthcare industry.
Bit.bio is a synthetic biology company focused on revolutionizing cell therapies by providing consistent and functional human cells for research and medical applications. The company aims to democratize access to these cells through its patented opti-ox™ technology, which safely reprograms human induced pluripotent stem cells (iPSCs) into highly defined, mature cell types. By applying computational principles to biology, Bit.bio seeks to develop a scalable platform that produces consistent batches of human cells. This innovation has the potential to enhance drug discovery and research, moving away from traditional models to work directly with the cells impacted by human diseases. With a team of experts in stem cells, cellular reprogramming, and mathematical modeling, Bit.bio is positioned to support a new generation of cell and tissue therapies, ultimately contributing to advancements in health and medicine.
Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, that focuses on developing innovative CRISPR solutions for a variety of applications. The company offers DETECTR™, a diagnostic platform that identifies specific nucleic acids in samples, aiding in the detection of diseases such as bacterial infections, cancer, and viral infections. Additionally, Mammoth Biosciences provides CRISPR-Cas systems for genome editing, targeting therapeutic areas including immuno-oncology, autoimmune diseases, and liver diseases. By harnessing proprietary ultracompact proteins and leveraging advanced research and development, Mammoth aims to create affordable point-of-care tests and enhance diagnostics across healthcare, agriculture, and environmental monitoring. Co-founded by CRISPR pioneer Jennifer Doudna, the company has attracted significant investment from institutional and individual backers.
Tango Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cancer therapies through the principle of synthetic lethality. Established in 2014, the company aims to discover and target specific driver genes involved in cancer progression. Its research concentrates on three main areas: counteracting the loss of tumor suppressor genes, reversing cancer cells' ability to evade the immune system, and identifying effective drug combinations that outperform single-agent therapies. Tango's pipeline includes TNG908, a selective inhibitor of PRMT5 designed for cancer cells with an MTAP deletion, alongside other discovery programs like TNG462, TNG348, and TNG260, which target various cancer types with limited treatment options.
XinThera is a drug discovery company focused on building small molecule oncology and immunology pipeline.
Kriya Therapeutics, Inc. is a gene therapy company dedicated to designing and developing treatments for chronic diseases. Founded in 2019 and headquartered in Palo Alto, California, with an additional office in Durham, North Carolina, the company has established a fully integrated platform that consolidates the essential infrastructure and technology for creating, manufacturing, and developing gene therapies. Kriya Therapeutics employs a vector design platform that enhances its ability to undertake novel construct design, targeted sequence modification, and comprehensive data analysis. This approach aims to reduce immunogenicity and improve tissue specificity, ultimately enabling physicians to provide more effective therapeutic options for patients.
Element Biosciences, Inc. is a life science company based in San Diego, California, that specializes in developing innovative genetic analysis tools for research and diagnostics. Established in 2017, the company focuses on creating a modular and high-performing DNA sequencing platform designed to provide high-quality data and workflow flexibility. Their proprietary technology enhances the signal-to-noise ratio and incorporates advancements in surface chemistry, instrumentation, and biochemistry. This approach significantly reduces both operational and capital costs while ensuring superior sequencing data quality, thereby making next-generation sequencing technology more accessible to medical researchers and improving their research capabilities.
HealthVerity, Inc. is a technology company that provides software tools for discovering and integrating patient data, primarily serving the pharmaceutical industry, hospitals, and payers. Founded in 2014 and headquartered in Philadelphia, Pennsylvania, HealthVerity's platform enables healthcare organizations to manage fragmented patient data, ensuring accuracy through sophisticated identity resolution and matching capabilities. Its tools facilitate the rapid creation and exchange of healthcare and consumer data in a privacy-protecting manner, allowing stakeholders to gain insights into patient adherence and improve healthcare decision-making. The company also supports targeted outreach efforts and has formed strategic partnerships with entities like Parexel and Medidata Solutions to enhance its offerings.
23andMe, Inc. is a consumer genetics company based in Sunnyvale, California, founded in 2006. It offers DNA analysis services through home-based saliva collection kits, enabling consumers to explore their genetic ancestry, traits, and health predispositions. The company provides various services, including Health + Ancestry, which delivers insights into ancestry and genetic health risks, and Ancestry + Traits, which offers an ancestry breakdown along with reports on over 30 traits. Additionally, 23andMe markets its data to researchers and scientists, providing them with categorized and searchable genetic information. The firm aims to enhance understanding of the human genome and its implications for health and ancestry. Through its consumer and research services, 23andMe seeks to make genetic information accessible and meaningful to individuals and professionals alike.
Quantum-Si is focused on revolutionizing the growing field of proteomics. The company’s suite of technologies are powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing.
Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities. It uses genomics, proteomics, structural biology, and computational chemistry to map and modulate protein communities. Interline leverages recent advancements in these technologies, as well as collaborations with leading academic groups, to develop a precision medicine platform focused on three essential areas, genomics, communities, and modulators. The South San Francisco, California-located company was founded by Zach Sweeney in 2020.
Aetion, Inc. is a healthcare analytics company that specializes in generating real-world evidence (RWE) through its Aetion Evidence Platform. This platform analyzes data from diverse clinical and financial interactions within the healthcare system, including claims, electronic health records, and clinical trials. By utilizing its patented rapid-cycle analytics technology, Aetion provides valuable insights to life sciences companies, payers, and healthcare providers, enabling them to assess the effectiveness and value of medical treatments. This facilitates collaboration among stakeholders to make informed decisions regarding patient care that is both clinically effective and cost-efficient. Founded in 2012 and headquartered in New York City, Aetion has established partnerships with various investors and organizations, including a strategic collaboration with McKesson. The company caters to a global clientele, including biopharmaceutical firms and academic institutions.
Eikon Therapeutics, Inc. is a biopharmaceutical company based in Hayward, California, focused on developing innovative treatments for chronic and life-threatening diseases. Founded in 2019, the company employs advanced super-resolution microscopy and live-cell imaging techniques to discover drugs targeting previously intractable proteins. By integrating biology, engineering, and chemistry, Eikon Therapeutics aims to enhance the understanding of cellular processes and improve drug discovery efficiency. Its proprietary platforms allow for the sensitive identification of compound-protein interactions, enabling the direct measurement of how chemical compounds affect individual proteins in live cells. This novel approach seeks to unlock new therapeutic opportunities and expand the company's pipeline of potential medications.
Identifeye is creating prediction models that combine multiple retinal imaging modalities with expert annotations to create comprehensive and non-invasive health assessments. Identifeye Health is a part of the 4Catalyzer accelerator, which is dedicated to improving patient care globally. It has offices in Guilford, Connecticut, New York City, and Palo Alto, California.
Invivyd is a biopharmaceutical company committed to developing antibody-based therapies aimed at providing protection against serious viral infectious diseases. The company focuses on creating solutions that go beyond naturally occurring immunity, particularly in response to viral threats with pandemic potential, starting with SARS-CoV-2. Its product pipeline includes ADG20, which is designed for the treatment and prevention of COVID-19, and VYD222, a monoclonal antibody engineered for enhanced potency and broad coverage. By prioritizing rapid and enduring therapeutic options, Invivyd aims to safeguard vulnerable populations from the severe impacts of circulating viral infections.
Theseus Pharmaceuticals is a biopharmaceutical company dedicated to enhancing the lives of cancer patients by discovering, developing, and commercializing innovative targeted therapies. The company's primary focus is on addressing drug resistance mutations in key driver oncogenes, which are mutated genes that contribute to the progression of cancer. By leveraging advanced technologies, Theseus Pharmaceuticals aims to create transformative treatments that can overcome challenges associated with existing therapies, thereby improving patient outcomes in oncology.
Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, the company is focused on developing advanced CRISPR enzymes, specifically its proprietary MADzymes, to facilitate precision gene editing. Inscripta has created the first benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that enable fully automated workflows for massively parallel editing of single cells. This innovative platform aims to empower scientists by overcoming existing technical and licensing challenges in gene editing research. By providing tools that allow for the generation of extensive libraries of designer proteins and genome variants, Inscripta supports researchers in designing, engineering, and evaluating genetic modifications with unprecedented ease and efficiency.
Crossover Health, Inc. provides comprehensive workplace healthcare services tailored for employers and their employees. Founded in 2010, the company is headquartered in Aliso Viejo, California, with health centers located in various regions, including Silicon Valley. Crossover Health offers a wide range of services, including primary care, urgent care, chronic disease management, preventive care, health risk assessments, and health education. Additionally, it provides ancillary services such as physical therapy, chiropractic care, acupuncture, and care coordination, along with health analytics and remote care options. The company's focus is on creating a positive employee care experience that promotes a healthy and motivated workforce while delivering financial benefits to organizations.
Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities. It uses genomics, proteomics, structural biology, and computational chemistry to map and modulate protein communities. Interline leverages recent advancements in these technologies, as well as collaborations with leading academic groups, to develop a precision medicine platform focused on three essential areas, genomics, communities, and modulators. The South San Francisco, California-located company was founded by Zach Sweeney in 2020.
Genomics plc is focused on transforming healthcare through advanced genomic analysis. The company employs sophisticated methodologies to analyze large integrated datasets of genomic and phenotypic information, aiming to enhance understanding of human biology. By leveraging genetic inference technology, Genomics plc seeks to identify new drug targets for serious diseases and assess individual disease risk. Their analytical platform enables the exploration of genomic sequence data, providing valuable insights that support pharmaceutical companies in reducing risks associated with drug development. This approach not only aims to improve healthcare outcomes but also sets a standard for how organizations and patients can benefit from genomic data.
Gemini Therapeutics, Inc. is a precision medicine company based in Cambridge, Massachusetts, established in 2015. The company is dedicated to developing innovative therapies for patients with dry age-related macular degeneration (AMD) and related rare genetic diseases. Gemini Therapeutics focuses on genetically defined conditions, ensuring that their therapeutic candidates are tailored to the specific molecular abnormalities found in patients with significant clinical needs. Their extensive pipeline includes a range of modalities such as monoclonal antibodies, recombinant proteins, and gene therapies. Supported by prominent life science investors and global academic collaborations, Gemini Therapeutics aims to create potentially first-in-class therapeutics to address unmet medical needs in the field of ophthalmology.
Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2019, the company utilizes artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By employing machine learning techniques, Delfi Diagnostics develops high-precision, non-invasive tests that aim to detect cancer at a stage when it is most treatable. Their technology enables healthcare professionals to recognize previously unrecognized cancer-associated cell-free DNA fragments, facilitating timely and effective treatment options for patients.
Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing innovative vaccines using its proprietary Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins into a single vaccine, thereby enhancing immune responses against a variety of infectious diseases affecting both children and adults. Affinivax targets several significant pathogens, including Streptococcus pneumoniae, bacterial nosocomial infections, Salmonella typhi, and Staphylococcus aureus. The company aims to create vaccines that not only provide broader disease coverage compared to existing options but also address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from the expertise of leading professionals in infectious diseases and vaccines, and it has received backing from the Bill & Melinda Gates Foundation, along with an exclusive license from Boston Children’s Hospital for its MAPS technology.
LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated platform that combines genomics, artificial intelligence, and synthetic biology. This innovative Avatar-Rx platform utilizes high-throughput microbiology, data science, machine learning, genome engineering, and automation to explore the fungal biosphere for novel genetically encoded molecules with specific biological functions. By integrating chemoinformatic-assisted drug optimization and advanced chemical synthesis with biotransformation, LifeMine Therapeutics aims to advance a pipeline of new medicines into development.
Kira Pharmaceuticals is a biotechnology company founded in 2017 and based in Suzhou, China. It specializes in developing complement-targeted therapies aimed at treating immune-mediated diseases. The company focuses on pioneering drug discovery related to the complement system, with the goal of providing transformative therapies for individuals suffering from complement-mediated conditions.
Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies that target RNA processing to address various diseases. Established in 2018 and based in Cambridge, Massachusetts, the company employs its proprietary biology platform to identify and prioritize therapeutic targets within RNA processing. Through its REMseq platform, Remix Therapeutics validates potential drug targets and optimizes chemical compounds for therapeutic use. The company's approach aims to reprogram RNA processing to control gene expression, thereby correcting, enhancing, or eliminating problematic gene messages. This enables healthcare providers to tackle the underlying causes of diseases, offering novel solutions to previously undruggable conditions.
EverlyWell develops do-it-yourself kits for a vast range of at-home regulatory-compliant diagnostic tests including food sensitivity, fertility, hormones, STDs, thyroid, and metabolism among the others, allowing users to perform tests at home and receive physician-reviewed results and insights on their mobile devices. EverlyWell also provides at-home covid testing.
SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. The company utilizes its proprietary technology platform, SomaScan, which allows for the measurement of proteins with a precision comparable to DNA measurement. This technology enhances the understanding of the molecular bases of health and disease, surpassing traditional genomic methods. SomaLogic develops and offers SOMAmers, modified nucleic acid-based protein-binding reagents, and provides diagnostic tests and protein measurement solutions for various diseases, including those in oncology, neurology, and cardiovascular health. Their products serve multiple applications, including life sciences research, therapeutic drug development, and clinical diagnostics, making significant contributions to the fields of biological and medical sciences. Founded in 1999, SomaLogic continues to advance the capabilities of proteomics in both research and clinical settings.
Pharvaris is a clinical-stage company dedicated to the discovery and development of therapies for rare diseases, particularly focusing on hereditary angioedema (HAE) and other conditions mediated by bradykinin. The company is advancing an oral bradykinin B2 receptor antagonist, with its lead candidate, PHA121, currently undergoing Phase 1 clinical trials. Pharvaris aims to provide new treatment options that offer alternatives to injected therapies for all sub-types of HAE. The company was co-founded by key individuals involved in the development of icatibant, a previously established treatment for HAE, ensuring a strong foundation in this therapeutic area.
Decibel Therapeutics is a developer of hearing disorder therapeutics intended to protect, repair and restore hearing. The company's therapeutics have provided insights into the link between hearing dysfunction and inner ear pathology and it has capabilities to encompass animal models, drug delivery to the inner ear, imaging, inner ear PK/PD modeling and measurement, bioinformatics, genetics and target identification, enabling patients to experience hearing loss therapies with different forms of hearing disorders for their recovery.
Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, that focuses on developing innovative CRISPR solutions for a variety of applications. The company offers DETECTR™, a diagnostic platform that identifies specific nucleic acids in samples, aiding in the detection of diseases such as bacterial infections, cancer, and viral infections. Additionally, Mammoth Biosciences provides CRISPR-Cas systems for genome editing, targeting therapeutic areas including immuno-oncology, autoimmune diseases, and liver diseases. By harnessing proprietary ultracompact proteins and leveraging advanced research and development, Mammoth aims to create affordable point-of-care tests and enhance diagnostics across healthcare, agriculture, and environmental monitoring. Co-founded by CRISPR pioneer Jennifer Doudna, the company has attracted significant investment from institutional and individual backers.
Sestina Bio, LLC is a biotechnology company founded in 2020 and based in Delaware. The company focuses on developing a synthetic biology platform that engineers yeast and bacteria to produce chemicals and pharmaceuticals. Sestina Bio integrates innovative advances in synthetic biology, data sciences, and bio-analytical systems to create solutions addressing significant global challenges, such as sustainable food production, clothing, and health for an expanding population. Their offerings include tools for genome editing, single-cell biology, and machine learning, which enhance researchers' capabilities to engineer and exploit new biological functions.
Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for estrogen receptor (ER) positive breast cancer. The company specializes in the discovery and commercialization of targeted treatments aimed at improving outcomes for women with cancer. Olema utilizes its extensive knowledge of endocrine-driven cancers and the molecular mechanisms of the ER to create drug candidates that are designed to outperform existing therapies. Currently, the company's product pipeline includes OP-1250 and OP-3136, both of which have completed discovery and preclinical studies. Olema's mission is to transform the standard of care for both pre- and post-menopausal women by providing more effective and convenient treatment options.
Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for estrogen receptor (ER) positive breast cancer. The company specializes in the discovery and commercialization of targeted treatments aimed at improving outcomes for women with cancer. Olema utilizes its extensive knowledge of endocrine-driven cancers and the molecular mechanisms of the ER to create drug candidates that are designed to outperform existing therapies. Currently, the company's product pipeline includes OP-1250 and OP-3136, both of which have completed discovery and preclinical studies. Olema's mission is to transform the standard of care for both pre- and post-menopausal women by providing more effective and convenient treatment options.
Tasso, Inc. is a Seattle-based company founded in 2012 that specializes in manufacturing blood sample collection devices designed for patient convenience. The company's innovative devices enable individuals to collect their own blood samples safely and easily at home, eliminating the need for clinic visits. These disposable, compact devices feature interchangeable cartridges that ensure proper blood preparation immediately upon sample collection. By allowing patients to manage their blood sampling process, Tasso aims to streamline blood-based diagnostics and enhance the overall experience of medical testing.
Bit.bio is a synthetic biology company focused on revolutionizing cell therapies by providing consistent and functional human cells for research and medical applications. The company aims to democratize access to these cells through its patented opti-ox™ technology, which safely reprograms human induced pluripotent stem cells (iPSCs) into highly defined, mature cell types. By applying computational principles to biology, Bit.bio seeks to develop a scalable platform that produces consistent batches of human cells. This innovation has the potential to enhance drug discovery and research, moving away from traditional models to work directly with the cells impacted by human diseases. With a team of experts in stem cells, cellular reprogramming, and mathematical modeling, Bit.bio is positioned to support a new generation of cell and tissue therapies, ultimately contributing to advancements in health and medicine.
Cue helps users track their health at the molecular level, revealing the interplay of activity, food, and sleep. Consumers can track five key health and lifestyle indicators: inflammation, vitamin D, fertility, influenza, and testosterone in just minutes, at home. The Cue sends the data via Bluetooth 4.0 to the user's smartphone, where the free Cue app reveals the interplay of activity, food, and sleep shaping the user at a molecular level.
DNAnexus, Inc. is a provider of cloud-based genome informatics and data management tools aimed at enterprises engaged in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and integration with clinical and phenotypic data, promoting seamless collaboration among users. Key offerings include MOSAIC Microbiome, a platform for collaborative microbiome research; DNAnexus Apollo, which focuses on clinico-genomic data exploration; and DNAnexus Titan, a comprehensive data analysis solution. Additionally, DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration. The Clinico-Genomic Data Solution program addresses the need for disease-specific datasets by building networks with healthcare partners to enhance diagnosis and treatment pathways. DNAnexus serves a diverse client base, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing therapies for patients with rare genetic diseases. The company is dedicated to addressing unmet medical needs, particularly in the realm of genetically defined conditions. Its lead product candidate, losmapimod, is a small molecule currently undergoing Phase 2b clinical trials for the treatment of facioscapulohumeral muscular dystrophy (FSHD), a progressive muscle-wasting disorder. Additionally, Fulcrum is developing FTX-6058, aimed at increasing fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia. The company also engages in research to identify drug targets for various conditions, including Duchenne muscular dystrophy and neurological diseases. Fulcrum Therapeutics has established collaborations with Acceleron Pharma Inc. and MyoKardia, Inc. to explore new therapeutic avenues in pulmonary disease and genetic cardiomyopathies, respectively. Founded in 2015, Fulcrum aims to enhance the quality of life for patients suffering from these challenging disorders.
Detect they build tools that empower people to understand their health.
Mindstrong operates a virtual mental health platform designed to enhance mental well-being through the integration of care, data, and technology. The platform addresses personal, societal, and economic challenges related to mental health, utilizing a biomarker panel that assesses brain function based on passive and continuous interaction patterns from human-computer interfaces. This innovative approach allows expert clinicians to deliver evidence-based interventions while offering personalized support and therapy, making mental health care more accessible. Mindstrong has successfully assisted thousands of individuals, including those with serious mental illnesses, in improving their mental health and overall quality of life.
Kriya Therapeutics, Inc. is a gene therapy company dedicated to designing and developing treatments for chronic diseases. Founded in 2019 and headquartered in Palo Alto, California, with an additional office in Durham, North Carolina, the company has established a fully integrated platform that consolidates the essential infrastructure and technology for creating, manufacturing, and developing gene therapies. Kriya Therapeutics employs a vector design platform that enhances its ability to undertake novel construct design, targeted sequence modification, and comprehensive data analysis. This approach aims to reduce immunogenicity and improve tissue specificity, ultimately enabling physicians to provide more effective therapeutic options for patients.
Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom, the company utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, using a repository of over 15,000 human brain tissue samples. This platform provides detailed expression and epigenetic data, allowing Cerevance to identify promising therapeutic targets for central nervous system diseases. Through its research, the company aims to advance new medicines that can potentially address the underlying mechanisms of these debilitating conditions.
Nurix Therapeutics is a biopharmaceutical company specializing in the discovery, development, and commercialization of small molecule therapies aimed at modulating cellular protein levels to treat cancer and immune disorders. The company's pipeline includes promising preclinical candidates such as NX-2127, an orally available Bruton’s tyrosine kinase degrader targeted at relapsed or refractory B-cell malignancies, and NX-1607, a Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology applications. Nurix's innovative drug discovery platform, DELigase, leverages its expertise in E3 ligases—enzymes that regulate protein modulation within cells—to identify and advance novel drug candidates. Founded in 2009 and based in San Francisco, Nurix Therapeutics aims to provide effective therapies for challenging diseases through its cutting-edge research and development efforts.
Vaxcyte, Inc. is a biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases globally. The company’s lead candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine. Additionally, Vaxcyte is advancing VAX-XP, which targets emerging strains that contribute to invasive pneumococcal disease and antibiotic resistance. Other notable candidates include VAX-A1, designed to protect against Group A Streptococcus infections, and VAX-PG, a therapeutic vaccine aimed at treating periodontal disease caused by Porphyromonas gingivalis. Vaxcyte utilizes a proprietary cell-free protein synthesis platform that enables the creation of protein carriers and antigens, enhancing vaccine development beyond conventional methods. Founded in 2013 and headquartered in Foster City, California, the company was previously known as SutroVax, Inc. before rebranding in May 2020.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative treatments for patients with hematological and musculoskeletal disorders that have significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, specifically anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is advancing KER-047, a small molecule therapy aimed at treating anemia caused by elevated hepcidin levels, as well as fibrodysplasia ossificans progressiva. Another candidate, KER-012, is being developed for conditions related to bone loss, such as osteoporosis and osteogenesis imperfecta, and for pulmonary arterial hypertension. Founded in 2015, Keros Therapeutics is headquartered in Lexington, Massachusetts.
evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniques we are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines.
ALX Oncology is a clinical-stage immuno-oncology company based in Burlingame, California, established in 2015. The company specializes in developing innovative therapies for cancer, particularly through its lead product candidate, ALX148, which targets the CD47 protein. This therapeutic aims to enhance the immune system's ability to detect and eliminate cancer cells, which often use CD47 as a mechanism to evade immune response. ALX148 is being investigated for its potential in treating various hematologic malignancies, including myelodysplastic syndromes and acute myeloid leukemia, as well as solid tumors such as head and neck squamous cell carcinoma and HER2-positive gastric cancer. The company’s research is rooted in advanced protein engineering, with a focus on creating next-generation therapies that minimize the hematologic toxicities associated with traditional CD47 blocking strategies.
PACT Pharma, Inc. is a biotechnology company focused on developing personalized cell-based therapies for cancer treatment, specifically through neoantigen-specific adoptive T-cell therapies aimed at solid tumors. The company utilizes bioinformatics to analyze the DNA and RNA of patients' tumors and normal tissues, identifying candidate neoantigen peptides that can stimulate targeted antitumor T-cell responses. By recognizing unique neo-epitopes associated with individual cancers, PACT Pharma enables the engineering of autologous T cells designed to specifically target and eliminate tumor cells expressing these neoantigens. Founded in 2016 and based in South San Francisco, California, PACT Pharma is dedicated to advancing innovative treatment options for patients with cancer.
Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing innovative gene therapies for both rare and prevalent diseases. Founded in 2016 and originally named Torus Therapeutics, the company focuses on treating conditions primarily affecting the liver and retina, as well as diseases of skeletal muscle, the central nervous system, and oncology. Generation Bio employs a proprietary non-viral platform that includes a high-capacity DNA construct known as closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP). This platform aims to deliver genetic payloads effectively across various tissues and allows for redosable treatments tailored to individual patient needs. Through its advanced manufacturing processes, Generation Bio seeks to expand access to gene therapies and provide durable solutions for patients with both rare and common diseases.
Element Biosciences, Inc. is a life science company based in San Diego, California, that specializes in developing innovative genetic analysis tools for research and diagnostics. Established in 2017, the company focuses on creating a modular and high-performing DNA sequencing platform designed to provide high-quality data and workflow flexibility. Their proprietary technology enhances the signal-to-noise ratio and incorporates advancements in surface chemistry, instrumentation, and biochemistry. This approach significantly reduces both operational and capital costs while ensuring superior sequencing data quality, thereby making next-generation sequencing technology more accessible to medical researchers and improving their research capabilities.
Kinnate Biopharma Inc. is a biopharmaceutical company based in San Diego, California, focused on developing small molecule kinase inhibitors for the treatment of genomically defined cancers. Founded in 2018, the company aims to create precision oncology therapeutics to address the needs of underserved patient populations. Kinnate's lead product candidate, KIN002787, is a rapidly accelerated fibrosarcoma inhibitor currently in preclinical development for lung cancer, melanoma, and other solid tumors. Additionally, the company is working on KIN003, which targets specific alterations in the FGFR2 and FGFR3 genes, and has other small molecule research programs, including a Cyclin-Dependent Kinase 12 inhibitor. Kinnate Biopharma employs expertise in structure-based drug discovery and translational research to advance its pipeline of candidates aimed at treating cancers associated with specific oncogenic alterations.